What was studied?
The phase 2 trial randomized 338 adults with obesity or overweight and a related condition to retatrutide study groups or placebo over 48 weeks.
What did the researchers report?
Retatrutide groups showed greater average weight reduction than placebo. Gastrointestinal adverse events and increases in heart rate were reported, making safety observations part of the interpretation.
What are the limits?
Phase 2 results are not a substitute for larger and longer studies. This paper alone cannot establish long-term safety, regulatory status or equivalence between the tested formulation and research-supply products.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.